Filtered By:
Drug: Aspirin
Procedure: Coronary Angioplasty
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 338 results found since Jan 2013.
Comparative efficacy and safety of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after percutaneous coronary intervention: A network meta-analysis of randomized controlled trials
Aimed to evaluate and compare the interactive effects of different antiplatelet or anticoagulation strategies in patients with chronic coronary syndromes (CCS) after percutaneous coronary intervention (PCI). Randomized controlled trials comparing different antiplatelet or anticoagulant strategies in patients with CCS after PCI were included. The primary outcomes were major adverse cardiovascular event (MACE), mortality, ischemic and bleeding events. Compared to aspirin alone, addition of prasugrel or ticagrelor to aspirin resulted in lower risk of myocardial infarction (MI) [odds ratio (OR): 0.38 (95% confidence interval 0...
Source: Frontiers in Pharmacology - September 30, 2022 Category: Drugs & Pharmacology Source Type: research
Body Mass Index and Major Adverse Events During Chronic Antiplatelet Monotherapy After Percutaneous Coronary Intervention With Drug-Eluting Stents - Results From the HOST-EXAM Trial
CONCLUSIONS: Lower BMI is associated with a higher risk of primary composite outcomes, which is primarily related to the events of all-cause death or major bleeding during chronic maintenance antiplatelet monotherapy after PCI with DES.PMID:36123011 | DOI:10.1253/circj.CJ-22-0344
Source: Circulation Journal - September 19, 2022 Category: Cardiology Authors: Ki-Bum Won Eun-Seok Shin Jeehoon Kang Han-Mo Yang Kyung Woo Park Kyoo-Rok Han Keon-Woong Moon Seok Kyu Oh Ung Kim Moo-Yong Rhee Doo-Il Kim Song-Yi Kim Sung-Yun Lee Jung-Kyu Han Bon-Kwon Koo Hyo-Soo Kim Source Type: research
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes Following Acute Myocardial Infarction
CONCLUSIONS: In patients with recent acute MI, 3 doses of asundexian, when added to aspirin plus a P2Y12 inhibitor, resulted in dose-dependent, near-complete inhibition of FXIa activity without a significant increase in bleeding and a low rate of ischemic events. These data support the investigation of asundexian at a dose of 50 mg daily in an adequately powered clinical trial of patients following acute MI.PMID:36030390 | DOI:10.1161/CIRCULATIONAHA.122.061612
Source: Circulation - August 28, 2022 Category: Cardiology Authors: Sunil V Rao Bodo Kirsch Deepak L Bhatt Andrzej Budaj Rosa Coppolecchia John Eikelboom Stefan K James W Schuyler Jones Bela Merkely Lars Keller Renicus S Hermanides Gianluca Campo Jos é Luis Ferreiro Taro Shibasaki Hardi Mundl John H Alexander Source Type: research
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study
CONCLUSIONS: In high-risk patients with prior CABG, ticagrelor monotherapy reduced bleeding without compromising ischaemic outcomes compared with ticagrelor plus aspirin.PMID:35979636 | DOI:10.4244/EIJ-D-22-00319
Source: EuroIntervention - August 18, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Gennaro Sardella Frans J Beerkens George Dangas Davide Cao Usman Baber Samantha Sartori David J Cohen Carlo Briguori Robert Gil Johny Nicolas Zhongjie Zhang Dariusz Dudek Vijay Kunadian Ran Kornowski Giora Weisz Bimmer Claessen Steven O Marx Javier Escane Source Type: research
Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant therapy and percutaneous coronary intervention
ConclusionsCombination of low-dose prasugrel and DOAC was associated with lower incidence of MI, ischemic stroke, and blood transfusion. Low-dose prasugrel may be feasible as part of triple therapy in patients undergoing PCI.
Source: PLoS One - July 28, 2022 Category: Biomedical Science Authors: Hideki Kitahara Source Type: research
Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial
CONCLUSIONS: In patients undergoing drug-eluting stent implantation for non-complex lesions, the benefits of 1-month DAPT followed by aspirin monotherapy for a composite of ischaemic and bleeding outcomes were found in patients with stable CAD, but not in those with ACS.CLINICALTRIALS: gov: NCT02513810.PMID:35470799 | DOI:10.4244/EIJ-D-22-00135
Source: EuroIntervention - April 26, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Yong-Joon Lee Jae Young Cho Kyeong Ho Yun Seung-Jun Lee Sung-Jin Hong Chul-Min Ahn Byeong-Keuk Kim Young-Guk Ko Donghoon Choi Myeong-Ki Hong Yangsoo Jang Jung-Sun Kim Source Type: research
Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study
CONCLUSIONS: Dual antithrombotic therapy is associated with a substantially lower risk of clinically relevant bleeding without a statistically significant penalty in ischaemic events.PMID:35370126 | DOI:10.4244/EIJ-D-21-00703
Source: EuroIntervention - April 4, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Willem Lambertus Bor Anne Johanna Wilhelmina de Veer Renske H Olie Sem A O F Rikken Dean R P P Chan Pin Yin Jean Paul R Herrman Mathias Vrolix Martijn Meuwissen Tom Vandendriessche Carlos van Mieghem Michael Magro Naoual Bennaghmouch Rick Hermanides Tom A Source Type: research
